VBI Vaccines Inc. (TSE:VBV – Get Free Report) traded down 5.1% during mid-day trading on Monday . The stock traded as low as C$4.82 and last traded at C$4.82. 1,300 shares were traded during mid-day trading, a decline of 64% from the average session volume of 3,637 shares. The stock had previously closed at C$5.08.
VBI Vaccines Price Performance
The stock has a market cap of C$308.86 million and a P/E ratio of -4.97. The company has a debt-to-equity ratio of 14.29, a current ratio of 2.64 and a quick ratio of 2.54.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Read More
- Five stocks we like better than VBI Vaccines
- What is the Dogs of the Dow Strategy? Overview and Examples
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Golden Cross Stocks: Pattern, Examples and Charts
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.